Tourette’s disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Tourette’s disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome https://clinicaltrials.eu/trial/study-on-the-effects-of-gemlapodect-for-adults-and-adolescents-with-tourette-syndrome/ Wed, 29 Apr 2026 14:48:00 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-gemlapodect-for-adults-and-adolescents-with-tourette-syndrome/ This clinical trial is focused on studying Tourette Syndrome, a condition characterized by repetitive movements or unwanted sounds (tics) that can’t be easily controlled. The study will evaluate the effectiveness and safety of a new treatment called Gemlapodect, which is a novel PD10A inhibitor. This medication is taken orally in the form of hard capsules. The trial will also include a comparison with a placebo to assess the true effects of the treatment.

The purpose of the study is to determine how well Gemlapodect works in reducing the severity of tics in both adults and adolescents with Tourette Syndrome. Participants will be involved in the study for a period of twelve weeks. During this time, they will receive either the active medication or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, various assessments will be conducted to monitor changes in tic severity and other related symptoms. These assessments will help researchers understand the impact of Gemlapodect on the participants’ condition. The study aims to provide valuable insights into the potential benefits and safety of this new treatment for individuals living with Tourette Syndrome.

]]> Study on the Effects of Dronabinol and Palmidrol for Adults with Tourette Syndrome https://clinicaltrials.eu/trial/study-on-the-effects-of-dronabinol-and-palmidrol-for-adults-with-tourette-syndrome/ Wed, 29 Apr 2026 14:27:41 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-dronabinol-and-palmidrol-for-adults-with-tourette-syndrome/ This clinical trial is focused on studying the effects of a new treatment for Tourette’s syndrome in adults. Tourette’s syndrome is a condition characterized by repetitive movements or unwanted sounds, known as tics, that cannot be easily controlled. The treatment being tested is called SCI-110, which is taken as a soft capsule. It contains two active substances: dronabinol and palmidrol. Dronabinol is a chemical that is similar to a substance found in cannabis, and palmidrol is a compound that may help reduce inflammation and pain.

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of SCI-110 in treating adults with Tourette’s syndrome. Participants in the study will take the medication daily. The study is designed to compare the effects of SCI-110 with a placebo, which looks like the medication but does not contain the active substances. This helps researchers understand how well the treatment works compared to no treatment. The study will last for a period of up to 12 weeks, during which participants will be monitored regularly to assess their response to the treatment and any side effects they may experience.

Throughout the study, participants will have regular check-ups to monitor their health, including vital signs like blood pressure and heart rate. The study aims to gather information on the number of adverse events, which are any unwanted effects that occur during the study. This information will help determine the safety and potential benefits of SCI-110 for people with Tourette’s syndrome. The results of this study could provide valuable insights into new treatment options for managing the symptoms of this condition.

]]> Study on Impulsivity Control in Adults with Tourette Syndrome Using [18F]-Altanserin and Aripiprazole https://clinicaltrials.eu/trial/study-on-impulsivity-control-in-adults-with-tourette-syndrome-using-18f-altanserin-and-aripiprazole/ Wed, 29 Apr 2026 14:26:25 +0000 https://clinicaltrials.eu/trial/study-on-impulsivity-control-in-adults-with-tourette-syndrome-using-18f-altanserin-and-aripiprazole/ This clinical trial is focused on studying the involvement of the serotonergic system in controlling impulsivity in individuals with Tourette disorder. The study will use two treatments: [18F]-Altanserin, which is administered as an injection, and Aripiprazole, which is taken orally. The purpose of the study is to explore the relationship between the availability of certain brain receptors and changes in impulsivity in adults with Tourette disorder.

Participants in the study will receive the treatments as part of their routine care. The study will involve monitoring changes in brain activity and impulsivity levels over time. This will help researchers understand how the treatments might affect impulsivity in people with Tourette disorder. The study will not involve any new or experimental treatments, as both [18F]-Altanserin and Aripiprazole are already used in medical practice.

The study will take place over a period of time, during which participants will undergo various assessments to measure changes in their condition. These assessments will include brain imaging techniques to observe how the brain responds to the treatments. The findings from this study could provide valuable insights into the management of impulsivity in Tourette disorder, potentially leading to improved treatment strategies in the future.

]]> Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder https://clinicaltrials.eu/trial/study-on-the-effects-of-ecopipam-hydrochloride-for-children-and-adolescents-with-tourettes-disorder/ Wed, 29 Apr 2026 14:24:13 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ecopipam-hydrochloride-for-children-and-adolescents-with-tourettes-disorder/ This clinical trial is focused on studying Tourette’s Disorder, a condition characterized by repetitive movements or sounds that are difficult to control, known as tics. The trial will evaluate the safety and effectiveness of a medication called Ecopipam, which is taken in tablet form. Ecopipam is being tested in different doses: 11.2 mg, 22.4 mg, 33.6 mg, 44.8 mg, 67.2 mg, and 89.6 mg. The study also includes a comparison with a placebo to assess the medication’s true effects.

The purpose of this study is to determine how well Ecopipam maintains its effectiveness in treating children and adolescents with Tourette’s Disorder. Participants in the study will be randomly assigned to receive either Ecopipam or a placebo. The study will be conducted over a period of several weeks, during which participants will take the medication orally. The trial will monitor the time it takes for symptoms to return, known as a relapse, in those taking Ecopipam compared to those taking a placebo.

This trial involves children, adolescents, and adults with Tourette’s Disorder. The study aims to provide valuable information on the long-term use of Ecopipam and its ability to help manage the symptoms of this disorder. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the medication’s effectiveness. The results of this trial could contribute to better treatment options for individuals living with Tourette’s Disorder.

]]> Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-ecopipam-hydrochloride-tablets-for-children-adolescents-and-adults-with-tourettes-disorder/ Wed, 29 Apr 2026 14:23:46 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-ecopipam-hydrochloride-tablets-for-children-adolescents-and-adults-with-tourettes-disorder/ This clinical trial is focused on studying the long-term safety of a medication called ecopipam in individuals with Tourette’s Disorder. Tourette’s Disorder is a condition characterized by repetitive movements or unwanted sounds, known as tics, that are difficult to control. The study involves children, adolescents, and adults who have previously participated in related studies and are eligible to continue. The medication being tested, ecopipam, is taken in the form of tablets and is designed to help manage the symptoms of Tourette’s Disorder.

The purpose of this study is to evaluate how safe and tolerable ecopipam is when used over a long period. Participants will take ecopipam tablets orally, which means they will swallow the tablets. The study will monitor participants for any side effects or issues that may arise from taking the medication over time. The study does not involve any comparison with a placebo, and all participants will receive the actual medication.

Participants in this study will be observed for a period of up to 105 days. During this time, they will take ecopipam tablets at varying doses, depending on their specific needs and previous study participation. The study aims to ensure that ecopipam is safe for long-term use in managing the symptoms of Tourette’s Disorder, providing valuable information for future treatment options.

]]>